27 results about "Ribosomal protein E-L30" patented technology

The present disclosure provides genetically modified plants, plant cells, or plant tissues wherein the plants, plant cells, or plant tissues comprise an exogenous nucleic acid comprising a nucleotide sequence encoding a 30S ribosomal protein or a homolog thereof, wherein the 30S ribosomal protein or the homolog thereof is expressed in the plant, plant cell, or plant tissue. The current disclosure provides methods of improving drought tolerance and water loss in a plant, plant cell, or plant tissue, the methods comprising an exogenous nucleic acid sequence encoding a 30S ribosomal protein or a homolog thereof, wherein the 30S ribosomal protein or the homolog thereof is expressed in the plant, plant cell, or plant tissue. Additionally, the current disclosure is describes to genetically modified plants, plant cells, or plant tissues wherein the plants, plant cells, or plant tissues comprise an exogenous nucleic acid comprising a nucleotide sequence encoding a cation / H+ exchanger 20 (CHX20) protein or a homolog thereof, wherein the nucleotide sequence is operably linked to a heterologous promoter, and the CHX20 protein or homolog thereof is expressed in the plant, plant cell, or plant tissue. Finally, the current disclosure provides methods of improving drought tolerance and water loss in a plant, plant cell, or plant tissue, the methods comprising an exogenous nucleic acid sequence encoding a CHX20 or a homolog thereof, wherein the CHX20 or the homolog thereof is expressed in the plant, plant cell, or plant tissue.

The invention relates to pichia pastoris for producing brazitame protein as well as a construction method and application of the pichia pastoris, and belongs to the technical field of microorganisms. ExpL SP is used as a signal peptide in pichia pastoris, heterologous expression of Brazilian sweet protein is carried out through an AOX1 promoter, the ExpL SP and a Pro region of an alpha mating factor are further fused and transformed to obtain a new signal peptide to enhance the secretion efficiency, and the new signal peptide and a ribosomal protein synthesis factor Bcy1 are co-expressed to improve the protein synthesis capacity. The constructed pichia pastoris can be used for efficiently secreting the Brazilian sweet protein, the problems that in the prior art, when microorganisms are used for fermenting the Brazilian sweet protein, the Brazilian sweet protein is mistakenly folded, the sweet taste is reduced or lost are solved, the shake flask yield is stabilized at 450 mg / L, the fermentation tank yield reaches 5.215 g / L, and a high-cost-performance scheme is provided for industrial production of the Brazilian sweet protein.

The invention relates to an application of zebrafish 80S ribosomal protein 7oyb in influence on inhibition of zebrafish embryo fibroblast proliferation by DON, and belongs to the technical field of molecular biology, the application is characterized in that the binding of vomitoxin and zebrafish ribosomal protein 7oyb is interfered by influencing the binding site of the vomitoxin on the zebrafish 80S ribosomal protein 7oyb, so that the zebrafish embryo fibroblast proliferation is inhibited, and the zebrafish embryo fibroblast proliferation is inhibited. The specific combination is as follows: the vomitoxin forms hydrogen bonds with nucleotides G17192, C17202 and C17312 on the 18s RNA, and forms hydrophobic interaction with PRO90 and HIS92 of G15932 and 40S ribosomal protein S19 on the 18s RNA; the invention also provides application of vomitoxin in inhibition of zebrafish embryo fibroblast proliferation. According to the application disclosed by the invention, acting sites of the DON in inhibition of zebrafish embryo fibroblast proliferation are found for the first time, and the problem that the DON inhibits the zebrafish embryo fibroblast proliferation can be solved by interfering the combination of the sites and the DON.

Provided is a method of identifying a serovar of Salmonella bacteria including a step of subjecting a sample containing microorganisms to mass spectrometry to obtain a mass spectrum, a step of reading a mass-to-charge ratio m / z of a peak derived from a marker protein from the mass spectrum, and an identification step of identifying a serovar of Salmonella bacteria in the sample, based on the mass-to-charge ratio m / z, wherein the serovars of Salmonella bacteria are classified using cluster analysis using as an index the mass-to-charge ratio m / z derived from at least 12 types of ribosomal proteins S8, L15, L17, L21, L25, S7, SODa, peptidylprolyl isomerase, gns, YibT, YaiA and YciF as the marker proteins.

The invention belongs to the technical field of biology, and relates to a method for increasing protein expression quantity by enhancing formation of mRNA (messenger ribonucleic acid) ribosome compounds. The method comprises the following steps: constructing a recombinant expression vector containing a first expression element of a target protein gene controlled by a first inducible promoter and a second expression element of a ribosome bS1 protein gene controlled by a second inducible promoter, introducing the recombinant expression vector into a recombinant bacterium, firstly inducing the expression of the target protein, and then inducing the expression of the ribosome bS1 protein, thereby obtaining the ribosome bS1 protein. Finally, the purpose of improving the expression of the target protein is achieved. Therefore, the invention can be used for improving the expression of the target protein and has wide application value.

The invention provides application of a paeoniflorin photoaffinity probe in screening key target protein of paeoniflorin, and relates to the technical field of chemical proteomics. The paeoniflorin photoaffinity probe has a structure as shown in a formula I, and the paeoniflorin key target proteins are 40S ribosomal protein S3 and statin 2. The paeoniflorin photoaffinity probe is applied to screening of the paeoniflorin key target proteins, so that two target proteins combined with paeoniflorin in liver cells are successfully identified; the two target proteins are respectively 40S ribosomal protein S3 (RPS3) and statin 2 (PHB2), and the two target proteins participate in the protection effect of paeoniflorin on the liver, and have the key effects of oxidation resistance, inflammation resistance, immunoregulation and the like in liver diseases.

The present disclosure provides methods for inducing cellular quiescence—defined as a reversible arrest of cell proliferation—by inhibiting ribosome biogenesis. The methods involve administering a quiescence-inducing agent, such as a small molecule inhibitor, peptide, antisense oligonucleotide, or targeted degrader, that interferes with rRNA transcription, processing, ribosomal protein synthesis, or ribosome assembly. The agent may be applied to cultured cells, tissues, organs, or organoids, across a range of cell types and species. In some embodiments, the methods reduce metabolic activity and enhance stress resistance in non-dividing or post-mitotic cells. By slowing proliferation and / or metabolism while preserving viability, these methods enable improved preservation of cells, tissues, and organs-enhancing transplantation logistics, biobanking, regenerative medicine workflows, and biological transport. Additional applications include studies of cell cycle regulation, tissue regeneration, stress biology, aging, and induction of organismal hypometabolism (e.g., torpor or hibernation). The disclosure includes examples demonstrating quiescence induction using chemical biology systems, pharmacological agents, and genetic approaches.

A self-inactivating lentiviral vector and method for treating or ameliorating Diamond-Blackfan anemia syndrome. The self-inactivating lentiviral vector includes nucleic acids encoding ribosomal protein S19 operably linked to an EF1α promoter or a MND promoter, wherein the nucleic acids encoding RPS19 are codon optimized for expression in human cells and are devoid of aberrant splice acceptor sites, thereby improving the safety and efficacy of the lentiviral vector.

The present invention discloses a ribosomal protein PpRPL12 in sand pear and its application in improving the disease resistance of plants. The present invention screens out a ribosomal protein PpRPL12 from sand pear that has a positive effect on resistance to pear black spot. The present invention uses an overexpression vector and a virus silencing vector constructed with the coding gene of the ribosomal protein PpRPL12 to verify the function of plant resistance to pear black spot. The results show that the resistance of pear callus and positive Arabidopsis plants with the coding gene to pear black spot is significantly higher than that of wild-type callus and wild-type Arabidopsis plants. PpRPL12 After silencing, it was found that the wild-type Pyrus betulus seedlings had better resistance to pear black spot than the silenced Pyrus betulus seedlings, which proved that the ribosomal protein PpRPL12 and its encoding gene of the present invention have important application value in the research of improving the resistance of plants to pear black spot.

The invention provides a marker for detecting quality deterioration of stored millet. The marker is 60S ribosomal protein L18a and / or 40S ribosomal protein S4. The marker provided by the invention can be used for accurately and conveniently detecting the quality deterioration condition of the stored millet, and is of great significance to food safety and production of grain enterprises.

The invention belongs to the technical field of gene engineering, and particularly relates to a ribosomal protein N'mutant and application thereof. The ribosomal protein N'mutant is subjected to Y190D mutation, and after the ribosomal protein N 'expressed by a production strain is subjected to Y190D mutation, the yield of LNT II is increased by 28.6%, the yield of LNnT is increased by 50%, the yield of LNT is increased by 92.3%, the yield of 3'-SL is increased by 13.8%, and the yield of 6 '-SL is increased by 20%. Therefore, after the 190th amino acid of the PriA is changed from tyrosine to aspartic acid, the production capacity of the PriA is improved, and when the PriA is applied to escherichia coli for producing the human milk oligosaccharide, the yield of the human milk oligosaccharide is remarkably improved finally.

The invention relates to the technical field of insect molecular biology, and particularly provides a real-time fluorescent quantitative PCR (Polymerase Chain Reaction) reference gene of small blue-and-white chamaecyparis and application thereof. The method comprises the following steps: selecting seven candidate reference genes for fluorescent quantitative PCR (Polymerase Chain Reaction) analysis by taking different tissues of the small blue-and-white turtle as materials, performing gene stability evaluation on the Ct value of each candidate gene by adopting a delta Ct method, geNorm, NormFinder, BestKeeper and RefFinder, and screening to obtain the fluorescent quantitative PCR reference gene ribosomal protein S3 (RPS3) and ribosomal protein L31 (RPL31) which are stably expressed in different tissues of the small blue-and-white turtle. The reference gene is suitable for fluorescent quantitative PCR of different tissues of small blue-and-white chamaecyparis, and provides a basic support for subsequent gene function research.

The application discloses a method for engineering regulation of mRNA translation efficiency based on ribosome S1 protein acylation modification, and belongs to the field of genetic engineering and microbial protein expression. The method comprises the following steps: regulating the translation efficiency of mRNAs by modifying the acylation site of ribosome S1 protein; dynamically regulating the recruitment and translation efficiency of specific mRNAs by screening and identifying SBS sequences with different intensities under different acylation states of ribosome S1 protein; regulating the translation efficiency of specific mRNAs by the interaction force between ribosome S1 protein and SBS sequences; and dynamically regulating the translation efficiency of specific mRNAs by dynamically adjusting the acylation level of ribosome S1 protein. The application regulates the interaction between ribosome S1 protein acylation modification and SBS sequence optimization in the translation initiation process and influences the translation efficiency, which provides a new idea for designing a novel translation regulation element and improving the expression level of mRNAs.

The invention relates to the technical field of tumor immunotherapy, in particular to an RPL39L gene and application of a gene inhibitor of the RPL39L gene, and the RPL39L gene comprises an RPL39L gene knockout agent and small interfering RNA (Ribonucleic Acid) targeting the RPL39L gene. According to the invention, the cancer testosterone gene RPL39L is found to be ribosomeST for forming spermatogenic cell specific ribosomeST for the first time, and can regulate and control a plurality of downstream cancer testosterone genes. A gene inhibitor and small interfering RNA are designed for the RPL39L, the RPL39L is knocked out from various tumor cells such as osteosarcoma, colorectal cancer, leukemia and glioma by using a CRISPR / Cas9 technology, and the influence on the proliferation ability and migration ability of the tumor cells after the RPL39L is knocked out is proved in vitro; and shRNA of a target RPL39L coding region is designed, so that the expression level of the RPL39L in tumor cells is successfully inhibited, and the inhibition effect of the shRNA on the growth of the tumor cells is proved in vitro. The invention provides an effective means for inhibiting the expression of the cancer testosterone gene regulatory factor from the upstream, and has extremely important significance and application prospect in tumor treatment.

Provided are methods for using chimeric proteins to produce RNA modifications that can be detected by sequencing methods, including methods detecting relative translation rates of various mRNAs. Also provided herein are compositions comprising chimeric proteins, wherein the chimeric proteins comprise a RNA editing protein and a ribosomal protein.

The invention is applicable to the technical field of biology, and provides a streptococcus suis type 2 multi-epitope inhalation type subunit vaccine and application thereof. According to the invention, 4 CTL epitopes, 7 HTL epitopes and 6 B cell epitopes are screened out aiming at conserved epitopes of SS2 virulence factors SSU05-1022 and SpaA, the epitopes are fused by AAY / GPGPG / EAAAK linkers, L7 / L12 ribosomal protein is introduced as an adjuvant, and the inhalation type subunit vaccine 1022-SpaA V3 is constructed; the vaccine can improve the levels of sIgA and serum IgG of respiratory mucosa and activate related immune cells by virtue of 60 micrograms of intranasal primary immunization-enhanced immunization, so that a mucosa and system dual immune mechanism is formed; the survival rate of mice after SS2 multi-strain challenge reaches up to 100%, and the bacterial load can be reduced; and the vaccine is safe and non-toxic, is inhaled, saves cost and is suitable for industrial large-scale production.

The present invention relates to a method for identifying a pharmaceutically active compound that modulates the rpL23-dependent translation of at least one mRNA in a mammalian cell, in particular the mRNA encoding the mutated TP53 protein. The at least one mRNA may include a premature termination codon (PTC) or undergo premature translation termination. Furthermore, a screening system, methods for treating or preventing a disease or condition, such as cancer, and screened compounds or derivatives thereof are provided.

The invention provides application of Escherichia coli 50S ribosome subunit protein coding genes rmF and rplX in the aspect of improving the growth rate of prokaryotic expression bacteria, and particularly relates to an Escherichia coli 50S ribosome subunit protein L32 coding gene rmF as shown in SEQ ID NO: 2, an Escherichia coli 50S ribosome subunit protein L24 coding gene rplX as shown in SEQ ID NO: 4 and application of coding proteins of the Escherichia coli 50S ribosome subunit protein L24 coding gene rplX. It is found that after rmF and rplX genes are transferred into a prokaryotic expression strain, the growth rate of the prokaryotic expression strain under normal conditions can be increased. The engineering strain is high in growth rate and high in expression efficiency, and can be used as an important biological resource in related gene engineering.

To provide a polypeptide corresponding in sequence homology to an active region of a 40s ribosomal protein S2 ("RPS2") that is beneficial as a therapeutic for oral and iv administration.SOLUTION: Provided is an isolated polypeptide that comprises or consists of a 40s ribosomal protein S2 (RPS2) or a fragment thereof, having a specific amino acid sequence.SELECTED DRAWING: Figure 1

The invention discloses application of ribosomal proteins RPS10 and RPS27A in regulating cell growth and radiosensitivity, and belongs to the technical field of biology. In order to research the effects of specific RPs in the aspects of regulating and controlling cell proliferation, survival and radiosensitivity, peripheral blood of a human body is subjected to gamma-ray irradiation, complete transcriptome sequencing is performed on the peripheral blood before and after irradiation after irradiation, and it is found that the expression levels of various RPs genes such as RPS10, RPS27A, RPL27 and RPL35 are remarkably changed after irradiation; then, functional research is carried out on RPS10, RPS27A, RPL27 and RPL35 genes in HeLa cells, and it is found that the RPS10 and RPS27A genes have the important regulating effect on cell proliferation and survival.

The invention belongs to the field of anticancer active natural components, and particularly relates to anticancer active glycoprotein, a preparation method and application of the anticancer active glycoprotein and an anti-female cancer medicine, and the anticancer active glycoprotein is protein chemically bonded with selenium and polysaccharide. The protein comprises a peroxidase structural domain protein, RNA dependent RNA polymerase, a nucleolus 278 pre-rRNA processed Urb / Npa2 C-terminal structural domain protein and a ribosomal protein S12; the polysaccharide chain is a sugar unit fragment with a structure shown in a formula 1; hydroxyl in the polysaccharide is connected with at least one amino acid of aspartic acid, valine, glutamic acid, arginine, lysine and serine in the protein through a hydrogen bond; the selenium bond comprises at least one of Se = O and Se-C-O. The invention provides a selenoglycoprotein component with a brand new structure, and further research shows that the selenoglycoprotein component can specifically inhibit female cancer cells and has relatively low normal cell inhibitory activity.

The invention provides a method for predicting myocarditis by using circular RNAcirc0071542 and ribosomal protein RPL13A. The method comprises the following steps: a) obtaining a biological sample of a subject; b) detecting the expression level of circACSL1 in the biological sample; c) comparing the expression level of the circACSL1 with a reference value from a healthy control; and d) when the expression level of the circACSL1 is higher than the reference value, judging that the subject has a myocarditis risk or is in a myocarditis state according to a difference value between the expression level of the circACSL1 and the reference value. The circACSL1 expression level is compared with the typical expression range of a dilated cardiomyopathy (DCM) subject to generate differential diagnosis data, and the expression difference of the marker between myocarditis and DCM can be utilized to effectively assist in clinically distinguishing the two diseases with different treatment strategies and prognosis but similar clinical manifestations.

The application belongs to the field of anticancer active natural ingredients, and particularly relates to an anticancer active glycoprotein, a preparation method and application thereof, and an anticancer drug for female cancer, wherein the anticancer active glycoprotein is a protein chemically bonded with selenium and polysaccharide, the protein includes a peroxidase domain protein, an RNA-dependent RNA polymerase, a nucleolar 278 pre-rRNA processing Urb / Npa2 C-terminal domain-containing protein, and a ribosomal protein S12; the polysaccharide chain is a sugar unit fragment with a structure of formula 1; the hydroxyl in the polysaccharide is connected to at least one amino acid in aspartic acid, valine, glutamic acid, arginine, lysine and serine in the protein through a hydrogen bond; and the selenium bond includes at least one of Se=O and Se-C-O. The application provides a novel structure of selenium glycoprotein ingredient, and further research shows that the ingredient can specifically inhibit female cancer cells and has a lower normal cell inhibition activity.

The application belongs to the technical field of biotechnology, and provides a Streptococcus suis type 2 (SS2) multi-epitope inhalation subunit vaccine and application thereof.Four CTL epitopes, seven HTL epitopes and six B cell epitopes are screened from the conserved epitopes of SS2 virulence factors SSU05-1022 and SpaA, and the four CTL epitopes, the seven HTL epitopes and the six B cell epitopes are fused by AAY / GPGPG / EAAAK linkers and introduced into L7 / L12 ribosomal protein as an adjuvant to construct an inhalation subunit vaccine 1022-SpaA V3.The vaccine is intranasally primed and boosted at 60 μg, can improve respiratory mucosa sIgA and serum IgG levels, activate related immune cells, and form a mucosal and systemic double immune mechanism.The survival rate of mice after SS2 multi-strain challenge is up to 100%, and the bacterial load can be reduced.The vaccine is safe and non-toxic, inhalation can save cost, and is suitable for industrial scale production.

The application provides a preparation method of 30S ribosomal protein S1 and use of the 30S ribosomal protein S1 as an antibacterial synergist, and belongs to the technical field of biological medicines. The 30S ribosomal protein S1 in the application is a bioactive protein produced by Acinetobacter bacteria, and has the effect of enhancing the antibacterial capacity of antibiotics. In the process of being combined with streptomycin sulfate, the 30S ribosomal protein S1 greatly enhances the inhibiting capacity of streptomycin sulfate on avian pathogenic E.coli without showing the effect of inhibiting bacteria itself, which lays a foundation for future practical application, and also plays a reference role for the development of new antibacterial synergists.

The application belongs to the technical field of genetic engineering, and particularly relates to a ribosomal protein N' mutant and application thereof. The ribosomal protein N' mutant is subjected to Y190D mutation. When the ribosomal protein N' expressed by a production strain is subjected to Y190D mutation, the production of LNT II is increased by 28.6%, the production of LNnT is increased by 50%, the production of LNT is increased by 92.3%, the production of 3'-SL is increased by 13.8%, and the production of 6'-SL is increased by 20%. It can be seen that after the 190th amino acid of PriA is changed from tyrosine to aspartic acid, the production capacity is improved. When the ribosomal protein N' mutant is applied to an Escherichia coli for producing human milk oligosaccharides, the production of human milk oligosaccharides is significantly improved.

In the present invention, when there is a peak of m / z 6766 + / -permissible error of ribosomal protein L30 derived from Mycobacterium abscessus subsp. Boleti as a result of mass spectrometry of a bacterium to be detected of Mycobacterium abscessus, it is determined that the bacterium to be detected is subsp. Boleti (steps 6, 7), and if there is a peak of m / z 6766 + / -permissible error of ribosomal protein L30 derived from Mycobacterium abscessus (steps 6, 7), it is determined that the bacterium to be detected is subsp. Boleti (steps 6, 7). The method comprises the following steps: determining that a bacterium to be detected is subspecies massiliensis if a peak of m / z 8767 + / -allowable error of ribosomal protein L29 derived from the subspecies massiliensis of Mycobacterium abscessus exists (steps 8 and 9), and determining that the bacterium to be detected is subspecies abscessus of Mycobacterium abscessus if both are not present (step 10). As a result, the subspecies of Mycobacterium abscessus (Mycobacterium abscessus) can be accurately, simply and conveniently identified.